Rejuvenating sirtuins: The rise of a new family of cancer drug targets

Current Pharmaceutical Design

Volumn 19, Issue 4, 2013, Pages 614-623

  Bruzzone, Santina ^a   Parenti, Marco Daniele ^b   Grozio, Alessia ^a   Ballestrero, Alberto ^c   Bauer, Inga ^c   Del Rio, Alberto ^b   Nencioni, Alessio ^c  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Cancer; Drug design; Drug discovery; Epigenetics; Sirtuin modulators

Indexed keywords

2 [1 (3 AMIDINOTHIOPROPYL) 1H INDOL 3 YL] 3 (1 METHYL 1H INDOL 3 YL)MALEIMIDE; 3 (3,5 DIBROMO 4 HYDROXYBENZYLIDENE) 1,3 DIHYDRO 5 IODO 2 INDOLONE; AC 93253; ANTINEOPLASTIC AGENT; AURORA A KINASE; AURORA B KINASE; CAMBINOL; CISPLATIN; EX 527; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NF 675; NICOTINAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; SIRTINOL; SIRTUIN; SIRTUIN 1; SIRTUIN 2; SIRTUIN 3; SIRTUIN 4; SIRTUIN 5; SIRTUIN 6; SIRTUIN 7; SIRTUIN INHIBITOR; THIOBARBITURIC ACID DERIVATIVE; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BINDING SITE; CANCER CELL; CANCER RADIOTHERAPY; CELL PROLIFERATION; CHEMOSENSITIVITY; CYTOSOL; DNA REPAIR; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; METABOLISM; MOLECULAR LIBRARY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; STRUCTURE ACTIVITY RELATION; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; X RAY CRYSTALLOGRAPHY;

EID: 84876717815     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804581954     Document Type: Review

References (130)

1. Frye RA. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Biochem Biophys Res Commun 1999; 260:273-9.
2. Tanny JC, Dowd GJ, Huang J, Hilz H, Moazed D. An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell 1999; 99:735-45.
3. Imai S, Armstrong CM, Kaeberlein M, Guarente L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 2000; 403:795-800.
4. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460:587-91.
5. Dani N, Barbosa AJM, Del Rio A, Di Girolamo M. ADPribosylated proteins as old and new drug targets for anticancer therapy: the example of ARF6. Curr Pharm Des 2013; 19(4): 624-33.
6. Libert S, Pointer K, Bell EL, et al. SIRT1 activates MAO-A in the brain to mediate anxiety and exploratory drive. Cell 2011; 147:1459-72.
7. Wang RH, Sengupta K, Li C, et al. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 2008; 14:312-23.
8. Kim HS, Vassilopoulos A, Wang RH, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011; 20:487-99.
9. Kim HS, Patel K, Muldoon-Jacobs K, et al. SIRT3 is a mitochondria-localized tumor suppressor required for maintenance of mitochondrial integrity and metabolism during stress. Cancer Cell 2010; 17:41-52.
10. Finley LW, Carracedo A, Lee J, et al. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011; 19:416-28.
11. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23:2369-80.
12. Firestein R, Blander G, Michan S, et al. The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PloS One 2008; 3:e2020.
13. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 2003; 11:437-44.
14. Van Meter M, Mao Z, Gorbunova V, Seluanov A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 2011; 10:3153-8.
15. Kawahara TL, Michishita E, Adler AS, et al. SIRT6 links histone H3 lysine 9 deacetylation to NF-kappaB-dependent gene expression and organismal life span. Cell 2009; 136:62-74.
16. Zhong L, D'Urso A, Toiber D, et al. The histone deacetylase Sirt6 regulates glucose homeostasis via Hif1alpha. Cell 2010; 140:280-93.
17. Luo J, Nikolaev AY, Imai S, et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001; 107:137-48.
18. Vaziri H, Dessain SK, Ng Eaton E, et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001; 107:149-59.
19. Brunet A, Sweeney LB, Sturgill JF, et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004; 303:2011-5.
20. Cohen HY, Miller C, Bitterman KJ, et al. Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase. Science 2004; 305:390-2.
21. Langley E, Pearson M, Faretta M, et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J 2002; 21:2383-96.
22. Menssen A, Hydbring P, Kapelle K, et al. The c-MYC oncoprotein, the NAMPT enzyme, the SIRT1-inhibitor DBC1, and the SIRT1 deacetylase form a positive feedback loop. Proc Natl Acad Sci USA 2012; 109:E187-96.
23. Heltweg B, Gatbonton T, Schuler AD, et al. Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes. Cancer Res 2006; 66:4368-77.
24. Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13:454-63.
25. Cea M, Soncini D, Fruscione F, et al. Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. PloS One 2011; 6:e22739.
26. Wang B, Hasan MK, Alvarado E, Yuan H, Wu H, Chen WY. NAMPT overexpression in prostate cancer and its contribution to tumor cell survival and stress response. Oncogene 2011; 30:907-21.
27. Audrito V, Vaisitti T, Rossi D, et al. Nicotinamide blocks proliferation and induces apoptosis of chronic lymphocytic leukemia cells through activation of the p53/miR-34a/SIRT1 tumor suppressor network. Cancer Res 2011; 71:4473-83.
28. Yuan H, Wang Z, Li L, et al. Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis. Blood 2012; 119:1904-14.
29. Li L, Wang L, Li L, et al. Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib. Cancer Cell 2012; 21:266-81.
30. Peck B, Chen CY, Ho KK, et al. SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Mol Cancer Ther 2010; 9:844-55.
31. Li Y, Matsumori H, Nakayama Y, et al. SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activationdependent p300 decrease, eventually leading to apoptosis. Genes Cells 2011; 16:34-45.
32. Zhang Y, Au Q, Zhang M, Barber JR, Ng SC, Zhang B. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem Biophys Res Commun 2009; 386:729-33.
33. Dan L, Klimenkova O, Klimiankou M, et al. The role of Sirtuin 2 activation by nicotinamide phosphoribosyltransferase in the aberrant proliferation and survival of myeloid leukemia cells. Haematologica 2011; 97:551-9.
34. Inoue T, Nakayama Y, Yamada H, et al. SIRT2 downregulation confers resistance to microtubule inhibitors by prolonging chronic mitotic arrest. Cell cycle 2009; 8:1279-91.
35. Alhazzazi TY, Kamarajan P, Joo N, et al. Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer. Cancer 2011; 117:1670-8.
36. Mostoslavsky R, Chua KF, Lombard DB, et al. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124:315-29.
37. Jia G, Su L, Singhal S, Liu X. Emerging roles of SIRT6 on telomere maintenance, DNA repair, metabolism and mammalian aging. Mol Cell Biochem 2012; 364:345-50.
38. McCord RA, Michishita E, Hong T, et al. SIRT6 stabilizes DNAdependent protein kinase at chromatin for DNA double-strand break repair. Aging (Albany NY). 2009; 1:109-21.
39. Van Gool F, Galli M, Gueydan C, et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuindependent manner. Nat Med 2009; 15:206-10.
40. Truyers C, Kellen E, Arbyn M, et al. The use of human tissue in epidemiological research; ethical and legal considerations in two biobanks in Belgium. Med Health Care Philos 2010; 13:169-75.
41. Allavena P, Germano G, Marchesi F, Mantovani A. Chemokines in cancer related inflammation. Exp Cell Res 2011; 317:664-73.
42. Barber MF, Michishita-Kioi E, Xi Y, et al. SIRT7 links H3K18 deacetylation to maintenance of oncogenic transformation. Nature 2012; 487:114-8.
43. Cea M, Cagnetta A, Gobbi M, et al. New Insights into the Treatment of Multiple Myeloma with Histone Deacetylase Inhibitors. Curr Pharm Des 2013; 19(4): 734-44.
44. Min J, Landry J, Sternglanz R, Xu RM. Crystal structure of a SIR2 homolog-NAD complex. Cell 2001; 105:269-79.
45. Pan PW, Feldman JL, Devries MK, Dong A, Edwards AM, Denu JM. Structure and biochemical functions of SIRT6. J Biol Chem 2011; 286(16):14575-87.
46. Sanders BD, Jackson B, Marmorstein R. Structural basis for sirtuin function: what we know and what we don't. Biochim Biophys Acta 2010; 1804:1604-16.
47. Andreoli F, Barbosa AJM, Parenti MD, Del Rio A. Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives. Curr Pharm Des 2013; 19(4): 578-613.
48. Tervo AJ, Kyrylenko S, Niskanen P, et al. An in silico approach to discovering novel inhibitors of human sirtuin type 2. J Med Chem 2004; 47:6292-8.
49. Jung-Hynes B, Nihal M, Zhong W, Ahmad N. Role of sirtuin histone deacetylase SIRT1 in prostate cancer. A target for prostate cancer management via its inhibition? J Biol Chem 2009; 284:3823-32.
50. Jackson MD, Schmidt MT, Oppenheimer NJ, Denu JM. Mechanism of nicotinamide inhibition and transglycosidation by Sir2 histone/protein deacetylases. J Biol Chem 2003; 278:50985-98.
51. Schmidt MT, Smith BC, Jackson MD, Denu JM. Coenzyme specificity of Sir2 protein deacetylases: implications for physiological regulation. J Biol Chem 2004; 279:40122-9.
52. Fatkins DG, Monnot AD, Zheng W. Nepsilon-thioacetyl-lysine: a multi-facet functional probe for enzymatic protein lysine Nepsilondeacetylation. Bioorg Med Chem Lett 2006; 16:3651-6.
53. Jamonnak N, Fatkins DG, Wei L, Zheng W. N(epsilon)-methanesulfonyl-lysine as a non-hydrolyzable functional surrogate for N(epsilon)-acetyl-lysine. Org Biomol Chem 2007; 5:892-6.
54. Jamonnak N, Hirsch BM, Pang Y, Zheng W. Substrate specificity of SIRT1-catalyzed lysine Nepsilon-deacetylation reaction probed with the side chain modified Nepsilon-acetyl-lysine analogs. Bioorg Chem 2010; 38:17-25.
55. Smith BC, Denu JM. Acetyl-lysine analog peptides as mechanistic probes of protein deacetylases. The J Biol Chem 2007; 282:37256-65.
56. Smith BC, Settles B, Hallows WC, Craven MW, Denu JM. SIRT3 substrate specificity determined by peptide arrays and machine learning. ACS Chem Biol 2011; 6:146-57.
57. Kiviranta PH, Suuronen T, Wallen EA, et al. N(epsilon)-thioacetyllysine-containing tri-, tetra-, and pentapeptides as SIRT1 and SIRT2 inhibitors. J Med Chem 2009; 52:2153-6.
58. Huhtiniemi T, Suuronen T, Lahtela-Kakkonen M, et al. N(epsilon)-Modified lysine containing inhibitors for SIRT1 and SIRT2. Bioorg Med Chem 2010; 18:5616-25.
59. Suzuki T, Asaba T, Imai E, Tsumoto H, Nakagawa H, Miyata N. Identification of a cell-active non-peptide sirtuin inhibitor containing N-thioacetyl lysine. Bioorg Med Chem Lett 2009; 19:5670-2.
60. He B, Du J, Lin H. Thiosuccinyl peptides as sirt5-specific inhibitors. J Am Chem Soc 2012; 134:1922-5.
61. Grozinger CM, Chao ED, Blackwell HE, Moazed D, Schreiber SL. Identification of a class of small molecule inhibitors of the sirtuin family of NAD-dependent deacetylases by phenotypic screening. J Biol Chem 2001; 276:38837-43.
62. Ota H, Tokunaga E, Chang K, et al. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene 2006; 25:176-85.
63. Lara E, Mai A, Calvanese V, et al. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Oncogene 2009; 28:781-91.
64. Bedalov A, Gatbonton T, Irvine WP, Gottschling DE, Simon JA. Identification of a small molecule inhibitor of Sir2p. Proc Natl Acad Sci USA 2001; 98:15113-8.
65. Neugebauer RC, Uchiechowska U, Meier R, et al. Structureactivity studies on splitomicin derivatives as sirtuin inhibitors and computational prediction of binding mode. J Med Chem 2008; 51:1203-13.
66. Marshall GM, Liu PY, Gherardi S, et al. SIRT1 promotes N-Myc oncogenesis through a positive feedback loop involving the effects of MKP3 and ERK on N-Myc protein stability. PLoS Genet 2011; 7:e1002135.
67. Uciechowska U, Schemies J, Neugebauer RC, et al. Thiobarbiturates as sirtuin inhibitors: virtual screening, free-energy calculations, and biological testing. ChemMedChem 2008; 3:1965-76.
68. Napper AD, Hixon J, McDonagh T, et al. Discovery of indoles as potent and selective inhibitors of the deacetylase SIRT1. J Med Chem 2005; 48:8045-54.
69. Trapp J, Jochum A, Meier R, et al. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition. J Med Chem 2006; 49:7307-16.
70. Howitz KT, Bitterman KJ, Cohen HY, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191-6.
71. McGeary RP, Bennett AJ, Tran QB, Cosgrove KL, Ross BP. Suramin: clinical uses and structure-activity relationships. Mini Rev Med Chem 2008; 8:1384-94.
72. Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ 1998; 5:876-83.
73. Trapp J, Meier R, Hongwiset D, Kassack MU, Sippl W, Jung M. Structure-activity studies on suramin analogues as inhibitors of NAD+-dependent histone deacetylases (sirtuins). ChemMedChem 2007; 2:1419-31.
74. Schuetz A, Min J, Antoshenko T, et al. Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin. Structure 2007; 15:377-89.
75. Outeiro TF, Kontopoulos E, Altmann SM, et al. Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 2007; 317:516-9.
76. Mai A, Valente S, Meade S, et al. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J Med Chem 2009; 52:5496-504.
77. Tavares J, Ouaissi A, Kong Thoo Lin P, et al. Bisnaphthalimidopropyl derivatives as inhibitors of Leishmania SIR2 related protein 1. ChemMedChem 2010; 5:140-7.
78. Gey C, Kyrylenko S, Hennig L, et al. Phloroglucinol derivatives guttiferone G, aristoforin, and hyperforin: inhibitors of human sirtuins SIRT1 and SIRT2. Angew Chem Int Ed Engl 2007; 46:5219-22.
79. Oh WK, Cho KB, Hien TT, et al. Amurensin G, a potent natural SIRT1 inhibitor, rescues doxorubicin responsiveness via downregulation of multidrug resistance 1. Mol Pharmacol 2010; 78:855-64.
80. Kahyo T, Ichikawa S, Hatanaka T, Yamada MK, Setou M. A novel chalcone polyphenol inhibits the deacetylase activity of SIRT1 and cell growth in HEK293T cells. J Pharmacol Sci 2008; 108:364-71.
81. Gutierrez M, Andrianasolo EH, Shin WK, et al. Structural and synthetic investigations of tanikolide dimer, a SIRT2 selective inhibitor, and tanikolide seco-acid from the Madagascar marine cyanobacterium Lyngbya majuscula. J Org Chem 2009; 74:5267-75.
82. Neugebauer RC, Sippl W, Jung M. Inhibitors of NAD+ dependent histone deacetylases (sirtuins). Curr Pharm Des 2008; 14:562-73.
83. Cen Y. Sirtuins inhibitors: the approach to affinity and selectivity. Biochim Biophys Acta 2010; 1804:1635-44.
84. Lawson M, Uciechowska U, Schemies J, Rumpf T, Jung M, Sippl W. Inhibitors to understand molecular mechanisms of NAD(+)-dependent deacetylases (sirtuins). Biochim Biophys Acta 2010; 1799:726-39.
85. Chen L. Medicinal chemistry of sirtuin inhibitors. Curr Med Chem 2011; 18:1936-46.
86. Stunkel W, Campbell RM. Sirtuin 1 (SIRT1): the misunderstood HDAC. J Biomol Screen 2011; 16:1153-69.
87. Moniot S, Weyand M, Steegborn C. Structures, substrates, and regulators of Mammalian sirtuins-opportunities and challenges for drug development. Front Pharmacol 2012; 3:16.
88. Huhtiniemi T, Salo HS, Suuronen T, et al. Structure-based design of pseudopeptidic inhibitors for SIRT1 and SIRT2. J Med Chem 2011; 54:6456-68.
89. Schlicker C, Boanca G, Lakshminarasimhan M, Steegborn C. Structure-based development of novel sirtuin inhibitors. Aging (Albany NY) 2011; 3:852-72.
90. Sivaraman P, Mattegunta S, Subbaraju GV, Satyanarayana C, Padmanabhan B. Design of a novel nucleoside analog as potent inhibitor of the NAD dependent deacetylase, SIRT2. Syst Synth Biol 2010; 4:257-63.
91. Huhtiniemi T, Suuronen T, Rinne VM, et al. Oxadiazolecarbonylaminothioureas as SIRT1 and SIRT2 inhibitors. J Med Chem 2008; 51:4377-80.
92. Kiviranta PH, Leppanen J, Kyrylenko S, et al. N, N'-Bisbenzylidenebenzene-1,4-diamines and N, N'-Bisbenzylidenenaphthalene-1,4-diamines as Sirtuin Type 2 (SIRT2) Inhibitors. J Med Chem 2006; 49:7907-11.
93. Tervo AJ, Suuronen T, Kyrylenko S, et al. Discovering inhibitors of human sirtuin type 2: novel structural scaffolds. J Med Chem 2006; 49: 7239-41.
94. Barbosa AJ, Del Rio A. Freely accessible databases of commercial compounds for high-throughput virtual screenings. Curr Top Med Chem 2012; 12:886-77.
95. Del Rio A, Barbosa AJ, Caporuscio F, Mangiatordi GF. CoCoCo: a free suite of multiconformational chemical databases for highthroughput virtual screening purposes. Mol Biosyst 2010; 6:2122-8.
96. Mak L, Liggi S, Tan L, et al. Anti-cancer drug development: Computational strategies to identify and target proteins involved in cancer metabolism. Curr Pharm Des 2013; 19(4): 532-77.
97. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450:712-6.
98. Dai H, Kustigian L, Carney D, et al. SIRT1 activation by small molecules: kinetic and biophysical evidence for direct interaction of enzyme and activator. J Biol Chem 2010; 285:32695-703.
99. Gupta SC, Kim JH, Prasad S, Aggarwal BB. Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticals. Cancer Metastasis Rev 2010; 29:405-34.
100. Chauhan D, Bandi M, Singh AV, et al. Preclinical evaluation of a novel SIRT1 modulator SRT1720 in multiple myeloma cells. Br J Haematol 2011; 155:588-98.
101. Huber JL, McBurney MW, Distefano PS, McDonagh T. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Future Med Chem 2010;2:1751-9.
102. Borra MT, Smith BC, Denu JM. Mechanism of human SIRT1 activation by resveratrol. J Biol Chem 2005; 280:17187-95.
103. Kaeberlein M, McDonagh T, Heltweg B, et al. Substrate-specific activation of sirtuins by resveratrol. J Biol Chem 2005; 280:17038-45.
104. Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010; 285:8340-51.
105. Beher D, Wu J, Cumine S, et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 2009;74:619-24.
106. Park SJ, Ahmad F, Philp A, et al. Resveratrol ameliorates agingrelated metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell 2012; 148:421-33.
107. Price NL, Gomes AP, Ling AJY, et al. SIRT1 Is Required for AMPK Activation and the Beneficial Effects of Resveratrol on Mitochondrial Function. Cell Metab 2012; 15:675-90.
108. Denu JM. Fortifying the Link between SIRT1, Resveratrol, and Mitochondrial Function. Cell Metab 2012; 15:566-7.
109. Alcain FJ, Villalba JM. Sirtuin activators. Expert Opin Ther Pat 2009; 19:403-14.
110. Heltweg B, Trapp J, Jung M. In vitro assays for the determination of histone deacetylase activity. Methods 2005; 36:332-7.
111. Huber K, Schemies J, Uciechowska U, et al. Novel 3-arylideneindolin-2-ones as inhibitors of NAD+-dependent histone deacetylases (sirtuins). J Med Chem 2010; 53:1383-6.
112. Marcotte PA, Richardson PL, Guo J, et al. Fluorescence assay of SIRT protein deacetylases using an acetylated peptide substrate and a secondary trypsin reaction. Anal Biochem 2004; 332:90-9.
113. Sanders BD, Jackson B, Brent M, et al. Identification and characterization of novel sirtuin inhibitor scaffolds. Bioorg Med Chem 2009; 17:7031-41.
114. Rotili D, Mai A. Targeting Histone Demethylases: A New Avenue for the Fight against Cancer. Genes Cancer 2011; 2:663-79.
115. Kalle AM, Mallika A, Badiger J, Alinakhi, Talukdar P, Sachchidanand. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun 2010; 401:13-9.
116. Mai A, Massa S, Lavu S, et al. Design, synthesis, and biological evaluation of sirtinol analogues as class III histone/protein deacetylase (Sirtuin) inhibitors. J Med Chem 2005; 48:7789-95.
117. Medda F, Russell RJ, Higgins M, et al. Novel cambinol analogs as sirtuin inhibitors: synthesis, biological evaluation, and rationalization of activity. J Med Chem 2009; 52:2673-82.
118. Suzuki T, Imai K, Imai E, et al. Design, synthesis, enzyme inhibition, and tumor cell growth inhibition of 2-anilinobenzamide derivatives as SIRT1 inhibitors. Bioorg Med Chem 2009; 17:5900-5.
119. Borra MT, Denu JM. Quantitative assays for characterization of the Sir2 family of NAD(+)-dependent deacetylases. Methods Enzymol 2004; 376:171-87.
120. Liu Y, Gerber R, Wu J, Tsuruda T, McCarter JD. High-throughput assays for sirtuin enzymes: a microfluidic mobility shift assay and a bioluminescence assay. Anal Biochem 2008; 378:53-9.
121. McDonagh T, Hixon J, DiStefano PS, Curtis R, Napper AD. Microplate filtration assay for nicotinamide release from NAD using a boronic acid resin. Methods 2005; 36:346-50.
122. Smith BC, Hallows WC, Denu JM. A continuous microplate assay for sirtuins and nicotinamide-producing enzymes. Anal Biochem 2009; 394:101-9.
123. Fan Y, Hense M, Ludewig R, Weisgerber C, Scriba GK. Capillary electrophoresis-based sirtuin assay using non-peptide substrates. J Pharm Biomed Anal 2011; 54:772-8.
124. Fan Y, Ludewig R, Imhof D, Scriba GK. Development of a capillary electrophoresis-based assay of sirtuin enzymes. Electrophoresis 2008; 29:3717-23.
125. Fan Y, Ludewig R, Scriba GK. 9-Fluorenylmethoxycarbonyllabeled peptides as substrates in a capillary electrophoresis-based assay for sirtuin enzymes. Anal Biochem 2009; 387:243-8.
126. Solomon JM, Pasupuleti R, Xu L, et al. Inhibition of SIRT1 catalytic activity increases p53 acetylation but does not alter cell survival following DNA damage. Mol Cell Biol 2006; 26:28-38.
127. Suzuki T, Imai K, Nakagawa H, Miyata N. 2-Anilinobenzamides as SIRT inhibitors. ChemMedChem 2006; 1:1059-62.
128. Wynne Aherne G, Rowlands MG, Stimson L, Workman P. Assays for the identification and evaluation of histone acetyltransferase inhibitors. Methods 2002; 26:245-53.
129. Peterson FC, Chen D, Lytle BL, et al. Orphan macrodomain protein (human C6orf130) is an O-acyl-ADP-ribose deacylase: solution structure and catalytic properties. J Biol Chem 2011; 286:35955-65.
130. Chen D, Vollmar M, Rossi MN, et al. Identification of macrodomain proteins as novel O-acetyl-ADP-ribose deacetylases. J Biol Chem 2011; 286:13261-71.